多家巨头从美国私有化退市，中概股加速回归！

Core Viewpoint - The Chinese concept stock market is undergoing significant changes in 2025, characterized by a wave of privatizations and delistings from U.S. exchanges, while a number of small and medium-sized enterprises continue to seek global financing opportunities, particularly through listings in the U.S. and Hong Kong [3][4]. Group 1: Privatization and Delisting - Geely Automobile completed the privatization of Zeekr, which became a wholly-owned subsidiary and delisted from the NYSE. The privatization was marked by a rapid process, with 70.8% of Zeekr shareholders opting for shares and 29.2% for cash, totaling $701 million [6]. - Dada Group, part of the JD ecosystem, was privatized by JD Group at a valuation of $520 million, allowing for more strategic flexibility and deeper collaboration with JD in the instant retail market [7]. - Financial One Account pioneered dual delisting by completing its exit from both the NYSE and Hong Kong Stock Exchange, with a privatization deal valued at approximately HKD 1.69 billion, driven by long-term low stock prices and liquidity issues [7]. Group 2: Trends in U.S. Listings - In 2025, 63 Chinese companies went public in the U.S., raising approximately $1.12 billion, indicating a trend of increasing numbers but decreasing fundraising amounts, with an average fundraising of less than $20 million [9]. - The largest IPOs included Bawang Tea and Ascentage Pharma, raising $411 million and $126 million respectively, highlighting a shift towards smaller enterprises in the U.S. market [9][10]. - The outlook for 2026 is cautious, as new listing requirements from Nasdaq may lead to a decline in the number of Chinese companies able to meet these standards [10]. Group 3: Return to Hong Kong - The trend of Chinese companies returning to Hong Kong is gaining momentum, with companies like Pony.ai and Hesai achieving dual primary listings, which is becoming the mainstream return model [12]. - Hesai's IPO in Hong Kong was the largest in the global lidar industry to date, raising over HKD 4.16 billion (approximately $533 million) [12]. - Other companies, such as Tianjing Biopharma, are also planning to pursue dual listings in Hong Kong, indicating a broader trend of returning to Asian markets [12]. Group 4: Strategic Implications - Some analysts suggest that privatization followed by IPOs in Hong Kong or A-shares may allow companies to escape U.S. regulatory pressures and achieve better valuations in local markets [13].